Published in Int J Chron Obstruct Pulmon Dis on January 01, 2008
Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis (2009) 1.32
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis (2015) 0.99
Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Int J Chron Obstruct Pulmon Dis (2015) 0.87
Impact of bronchodilator therapy on exercise tolerance in COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.86
Effect of "add-on" interventions on exercise training in individuals with COPD: a systematic review. ERJ Open Res (2016) 0.81
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. Int J Chron Obstruct Pulmon Dis (2014) 0.77
Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians. Int J Gen Med (2011) 0.76
Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison. Adv Ther (2016) 0.76
Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf (2016) 0.75
Breathlessness with pulmonary metastases: a multimodal approach. J Adv Pract Oncol (2013) 0.75
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
Psychophysical bases of perceived exertion. Med Sci Sports Exerc (1982) 30.13
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
Global burden of COPD: risk factors, prevalence, and future trends. Lancet (2007) 9.50
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med (1995) 6.99
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med (2006) 5.65
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2007) 5.51
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest (2002) 3.82
Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 3.58
Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med (1997) 3.28
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J (2004) 3.19
Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis (1991) 2.95
Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.63
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest (2005) 2.15
Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax (1996) 1.94
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest (2005) 1.83
Physiologic responses to incremental and self-paced exercise in COPD: a comparison of three tests. Chest (2004) 1.63
Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1996) 1.63
Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. Respir Med (2007) 1.17
Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J (1999) 1.17
Physiologic factors that determine the health-related quality of life in patients with COPD. Chest (1996) 1.11
Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis (2008) 1.01
Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease. Thorax (2006) 0.91
Effects of rehabilitation on chest wall volume regulation during exercise in COPD patients. Eur Respir J (2006) 0.88
Determining the cause of dyspnoea: linguistic and biological descriptors. Chron Respir Dis (2006) 0.85
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med (2005) 4.95
Risk indexes for exacerbations and hospitalizations due to COPD. Chest (2007) 3.55
A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest (2002) 2.74
Cardiovascular safety of tiotropium in patients with COPD. Chest (2009) 2.70
Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 2.55
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest (2005) 2.15
Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest (2003) 1.90
Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest (2003) 1.85
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest (2005) 1.83
Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD (2004) 1.46
Evaluation of withdrawal of maintenance tiotropium in COPD. Respir Med (2009) 1.39
Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.38
Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema. Eur Respir J (2011) 1.22
Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema. Int J Chron Obstruct Pulmon Dis (2012) 1.15
Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med (2010) 1.11
Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest (2013) 1.09
Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (2011) 1.09
Efficacy of bronchoscopic thermal vapor ablation and lobar fissure completeness in patients with heterogeneous emphysema. Respiration (2012) 1.06
Ozone exposure increases eosinophilic airway response induced by previous allergen challenge. Am J Respir Crit Care Med (2002) 1.06
Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy (2005) 1.05
Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respir Med (2011) 1.02
The localized inflammatory response to bronchoscopic thermal vapor ablation. Respiration (2013) 0.97
Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res (2011) 0.96
Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD (2012) 0.95
Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis (2007) 0.95
Insurance status and patient behavior with asthma medications. J Asthma (2003) 0.94
Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf (2007) 0.92
Effect of obesity on constant workrate exercise in hyperinflated men with COPD. BMC Pulm Med (2010) 0.90
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung (2011) 0.87
Induced sputum is a reproducible method to assess airway inflammation in asthma. Mediators Inflamm (2002) 0.86
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84
Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting. Respir Med (2009) 0.84
Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res (2012) 0.83
Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study. Curr Med Res Opin (2007) 0.83
Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim Care Respir J (2008) 0.83
Development and implementation of treadmill exercise testing protocols in COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.83
Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease. JAMA (2009) 0.82
Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics (2004) 0.82
Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respir Med (2006) 0.81
Beclomethasone dipropionate blunts allergen-induced early increase in urinary LTE4. Eur J Clin Invest (2010) 0.80
Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease. Transl Res (2008) 0.80
Performance during constant workrate cycling exercise in women with COPD and hyperinflation. COPD (2009) 0.79
Comparison of human lung tissue mass measurements from ex vivo lungs and high resolution CT software analysis. BMC Pulm Med (2012) 0.79
Premature discontinuation during the UPLIFT study. Respir Med (2011) 0.79
Acute administration of bronchodilators on exercise tolerance in treated COPD patients. Pulm Pharmacol Ther (2010) 0.78
Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2009) 0.77
Analysis of sputum cell counts during spontaneous moderate exacerbations of asthma in comparison to the stable phase. J Asthma (2003) 0.77
Magnitude of late asthmatic response to allergen in relation to baseline and allergen-induced sputum eosinophilia in mild asthmatic patients. Ann Allergy Asthma Immunol (2008) 0.77
Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization. Pulm Pharmacol Ther (2005) 0.76
Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Int J Chron Obstruct Pulmon Dis (2011) 0.76
Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med (2012) 0.76
Noninvasive nocturnal ventilatory support in advanced lung disease from cystic fibrosis. Respir Care (2002) 0.75
Thermal effect of endoscopic thermal vapour ablation on the lung surface in human ex vivo tissue. Int J Hyperthermia (2012) 0.75
Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. Neurol Sci (2015) 0.75
Eletrocardiographic monitoring in COPD patients receiving tiotropium. COPD (2004) 0.75
Evaluation of energy in heated water vapor for the application of lung volume reduction in patients with severe emphysema. Respiration (2013) 0.75
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. Parkinsonism Relat Disord (2013) 0.75
Biological markers in induced sputum of patients with different phenotypes of chronic airway obstruction. Respiration (2008) 0.75